R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
R&A PSYINS, an independent insurance broker that provides insurance to the psychedelic industry, announced a strategic partnership with
This landmark partnership was established to address a paramount issue facing psychedelic medicinal businesses. While more state legislators are pushing forward psychedelic policy reform – opening the door for more therapists and clinicians, retreats, and investors to enter the space – it is extremely difficult for psychedelic medicinal businesses to access insurance in this current hardened insurance market, leaving them exposed to a wide spectrum of risks.
Psychedelic therapies are in the highest risk pool for malpractice and other claims. Ketamine clinics, therapists and other practitioners need to understand, mitigate, and protect themselves from these perils. For companies that manufacture, test and distribute psychedelics for medicinal purposes, there are a host of additional risks, particularly if the goal is to go public. In response, R&A PSYINS developed a risk management program that offers specialty lines of business and medical malpractice insurance policies, including Professional Liability/Errors & Omissions, General Liability, Directors & Officers Liability, Product Liability, IP Defense/Enforcement, Cyber Defense/Data Breach and Workers’ Compensation coverage.
Nucleus, which is wholly owned by the venture capital firm, Iter Investments, is comprised of technology, data, and media assets intended to deliver intelligence, education, and opportunities to psychedelic industry stakeholders. The company’s acquisition of Psychedelic Invest and Neuly in 2022 was the foundation for its robust ecosystem. With its proprietary search technology, vast database, and suite of educational assets, Nucleus is helping to propel transformative health treatments forward.
“Both of our companies are at the forefront of the psychedelic medicinal movement,” said
This new partnership will benefit all stakeholders in Nucleus’ robust ecosystem by providing them access to psychedelic industry insurance that will ensure they are fully protected and in compliance with state and federal HIPPA regulations.
“We couldn’t be more excited to partner with a company like R&A PSYINS,” said
###
About R&A PSYINS
R&A PSYINS is a division of
+1 401-368-6655
[email protected]
Visit us on social media:
LinkedIn



Aspire General Insurance Appoints Byron Storms as CEO and Chairman
MetLife Named One of America’s Most Just Companies
Advisor News
- Equitable launches 403(b) pooled employer plan to support nonprofits
- Financial FOMO is quietly straining relationships
- GDP growth to rebound in 2027-2029; markets to see more volatility in 2026
- Health-related costs are the greatest threat to retirement security
- Social Security literacy is crucial for advisors
More Advisor NewsAnnuity News
- MetLife to Announce First Quarter 2026 Results
- CT commissioner: 70% of policyholders covered in PHL liquidation plan
- ‘I get confused:’ Regulators ponder increasing illustration complexities
- Three ways the Corebridge/Equitable merger could shake up the annuity market
- Corebridge, Equitable merge to create potential new annuity sales king
More Annuity NewsHealth/Employee Benefits News
- Virginia insurance regulators order rate cuts for several Aflac policies
- State legislators continue to question HPH-HMSA deal
- Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates
- Virginia insurance regulators order Aflac rate cuts
- Providers wait for hundreds of millions in delayed Medicaid payments
More Health/Employee Benefits NewsLife Insurance News
- WoodmenLife 2025 annual report celebrates family, community and country
- Overcoming price objections by reframing costs
- Virginia insurance regulators order rate cuts for several Aflac policies
- AM Best Maintains Under Review With Positive Implications Status for The Fortegra Group, Inc.’s Insurance Subsidiaries
- Life insurance application activity sees record-breaking Q1
More Life Insurance News